Creating a safer topical treatment for infantile hemangioma
Official title: Developing a topical beta blocker formulation as a targeted therapeutic for infantile hemangioma
Funded at Arkayli Biopharma, INC. · NIH-11183962 · Data updated 2026-11-12
This study is testing a new skin treatment for infantile hemangioma, a common type of tumor in babies, to make it safer and more effective than the current oral medications.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arkayli Biopharma, INC. NIH-funded |
| Lab location | 1 site (Mount Airy, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $306,804 |
| NIH project number | 1R41HL177866-01A1 |
| Project ID | NIH-11183962 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants diagnosed with infantile hemangioma who may benefit from a topical treatment approach.
✕Less likely to help
Patients with hemangiomas that are not suitable for topical treatment or those who do not have infantile hemangioma may not benefit from this research.
What this research studies
This research focuses on developing a new topical formulation of a beta blocker specifically designed to treat infantile hemangioma, a common benign tumor in infants. The approach aims to provide a safer alternative to the currently used oral beta blockers by minimizing systemic exposure and potential side effects. The formulation is designed using advanced drug design techniques to enhance efficacy while ensuring safety for young patients. By targeting the treatment directly to the affected area, the goal is to reduce complications associated with this condition.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for infants with hemangiomas, reducing the risk of complications and improving overall outcomes.
How similar studies have gone: While oral beta blockers have been established as a standard treatment, this novel topical approach is relatively new and has not been widely tested in similar formulations.
Where this research is happening
-
Arkayli Biopharma, INC.
Mount Airy, United States Active
Researchers
- Principal investigator: Reno, Seth — Arkayli Biopharma, INC.
- Study coordinator: Reno, Seth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.